MEDIUM confidence
Researched 2026-07-28 12:52 · profile: researcher
Programme Thesis
The DayOne Accelerator funds early-stage healthtech startups that can solve pharmaceutical R&D challenges, offering equity-free support and access to Basel's pharma ecosystem to bridge innovations with industry needs. It exists to accelerate ventures that have a prototype ready for pharma engagement within 12-18 months, leveraging Basel's hub of Novartis and Roche.
Selection Criteria
- Pre-Seed to Series A stage with less than $10M in dilutive funding
- Prototype or product that can be offered to pharmaceutical companies within 12-18 months
- Solution addresses pharmaceutical R&D challenges (e.g., AI drug discovery, decentralized trials)
- International healthtech startups (digital health, MedTech, TechBio)
- Pharma-neutral approach: must be open to engaging with multiple pharma partners
- Potential for collaboration, partnership, or client relationships with pharma companies
Past Winners / Cohort Profiles
Past participants include Senseera (Noam Diamant, Head of Business Development), Oncoustics (CEO Beth Rogozinski), and Theremia (Co-founder & CEO Iris Maréchal). Archetypes are early-stage healthtech ventures with a clear pharma-facing value proposition, often in AI diagnostics, digital therapeutics, or clinical trial tools.
Ideal Candidate Fingerprint
A startup with a validated prototype in digital health, MedTech, or TechBio that directly addresses a pharma R&D bottleneck, has a clear go-to-market strategy for pharma clients, and is led by a team with domain expertise and a willingness to engage with Basel's ecosystem. The ideal applicant is pre-revenue to Series A, with less than $10M raised, and can demonstrate traction or pilot interest from pharma.
Recommended Framing
Eniola should position his TOPOLOGIX platform (ESM-2 delta-embeddings + Morgan fingerprints for drug-resistance mutation prediction) as a healthtech/TechBio tool that directly addresses a critical pharma R&D challenge: predicting resistance mutations early in drug development. His independent research track record, pre-registered studies, and Bayesian calibration methods show scientific rigor, while his software engineering skills (Python, HPC, production systems) demonstrate ability to deliver a prototype. Emphasize the Africa angle: drug resistance is a global health priority with high relevance to LMICs, and his Nigerian background adds unique perspective on neglected diseases.
Watch Out
The accelerator is for startups, not individual researchers; Eniola is an independent researcher without a formal startup entity. He has no co-founders or team, and his work is research-focused rather than product/company-building. The programme requires a prototype that can be offered to pharma within 12-18 months, which may be a stretch for his current academic-style outputs. Additionally, he is enrolled in an M.Sc. and may not have full-time availability for a 3-month hybrid programme.